Future Considerations for the mRNA–Lipid Nanoparticle Vaccine Platform

Botond Igyártó; Sonya Jacobsen; Sonia Ndeupen

doi:10.20944/preprints202012.0493.v1

Submitted:

17 December 2020

Posted:

21 December 2020

Read the latest preprint version here

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Preprint

Short Note

This version is not peer-reviewed.

Future Considerations for the mRNA–Lipid Nanoparticle Vaccine Platform

Botond Igyártó^*

,Sonya Jacobsen,Sonia Ndeupen

Botond Igyártó^*

,Sonya Jacobsen,Sonia Ndeupen

A peer-reviewed article of this preprint also exists.

Submitted:

17 December 2020

Posted:

21 December 2020

Read the latest preprint version here

Abstract

Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new vaccine platform used by two of the leading vaccine candidates against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology.

Keywords:

mRNA-LNP vaccines

;

side effects

;

dendritic cells

Subject:

Biology and Life Sciences - Biochemistry and Molecular Biology

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.